#ESMO26 @dplanchard 博士介绍了 FLAURA2 研究中 EGFR+ NSCLC 的 ctDNA 清除数据。osi/chemo 组基线 ctDNA 阳性比例为 69%，osi 单药组为 77%，两组 ctDNA 清除率相似。ctDNA 清除具有预后意义，但无论是否清除 ctDNA，均观察到了化疗获益。#ESMOAmbassadors
109 浏览 · 3 赞 · 1 转发 · 0 回复
Improving prevention of moderate to severe dermatologic adverse events in EGFR-mutant advanced NSCLC treated with first-line (1L) subcutaneous (SC) amivantamab + lazertinib: First results from a new COCOON cohort
https://esmocongress.esmo.orgExtended circulating tumor DNA (ctDNA) sequencing to optimize the selection between anti-EGFR rechallenge and other later lines in patients with RAS/BRAF wild-type metastatic colorectal cancer
https://esmocongress.esmo.org- **标题 / Title：** A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy
https://esmocongress.esmo.org来源：Stephen V Liu, MD · x.com